Hutchison China MediTechの営業利益
Hutchison China MediTechの営業利益は何ですか。
Hutchison China MediTech Ltd.の営業利益は-19.78%です。
営業利益の定義は何ですか。
営業利益率は、営業利益を純売上高で除したもので、パーセントで表しています。
Operating margin is an indicator of profitability and is often used to compare the profitability of companies and industries of differing sizes. Companies are collections of projects and markets, individual areas can be judged on how successful they are at adding to the corporate net profit. Not all projects are of equal size, however, and one way to adjust for size is to divide the profit by sales revenue. The resulting ratio is the percentage of sales revenue that gets 'returned' to the company as net profits after all the related costs of the activity are deducted.
LSEのセクタHealth Careにおける営業利益の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似の営業利益
- Yowieの営業利益は-19.88%です。
- China Southern Airlinesの営業利益は-19.88%です。
- China Dredging Environment Protectionの営業利益は-19.87%です。
- Irobot Corpの営業利益は-19.86%です。
- Grafenia Plcの営業利益は-19.84%です。
- Secoo Ltdの営業利益は-19.82%です。
- Hutchison China MediTechの営業利益は-19.78%です。
- Ourgame Internationalの営業利益は-19.74%です。
- Amryt Pharma plcの営業利益は-19.71%です。
- Osisko Gold Royalties Ltdの営業利益は-19.70%です。
- Amundi Index Solutions - Amundi MSCI USA UCITS ETF-C EURの営業利益は-19.69%です。
- Goldinの営業利益は-19.69%です。
- Certaraの営業利益は-19.69%です。